Yeo D, Hossain I, Lim ST, et al. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: an observational study. J Oncol Pharm Pract. 2018 Jan 1:1078155218763039. doi: 10.1177/1078155218763039. [Epub ahead of print].
2.
TerraultNABzowejNHChangKMet al.American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology2016; 63: 261–283.
3.
WangQKlenermanPSemmoN. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol2017; 2: 123–134.
4.
SuFHBaiCHChuFYet al.Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine2012; 30: 4034–4039.
5.
PaulSDicksteinASaxenaAet al.Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology2017; 66: 379–388.
6.
Jeon JW, Kim SM, Cho H, et al. Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation. Transplantation. 2018 Apr 5. doi: 10.1097/TP.0000000000002173. [Epub ahead of print].
7.
SuWJHoMCNiYHet al.High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr2009; 48: 203–208.
